Fox News contributor Dr. Janette Nesheiwat discusses metrics that show Americans are getting healthier on 'Fox News Live.' Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcohol effects , a new study suggests.
Glucagon-like peptide-1 receptor (GLP-1) agonists — which contain either semaglutide or liraglutide — are prescribed to treat type 2 diabetes and obesity, but previous studies have shown that people report decreased alcohol consumption when taking them. In a new study by the University of Eastern Finland and Karolinska Institutet in Sweden, researchers found that people with alcohol use disorder (AUD) were less likely to be hospitalized for alcohol or substance abuse-related conditions. DRINKING ALCOHOL IS LINKED TO SIX TYPES OF CANCER, EXPERTS SAY The researchers analyzed decades of data from 228,000 people in Sweden who had AUD, ranging in age from 16 to 64, according to a press release.
Studies have shown that people report decreased alcohol consumption when taking glucagon-like peptide-1 receptor (GLP-1) agonists. (iStock) For participants who had AUD, obesity and type 2 diabetes, the use of GLP-1 medications was linked to "substantially decreased risk of hospitalization due to AUD," the researchers wrote. Patients taking semaglutide (such as Ozempic and Wegovy) showed a 36% lower risk, and those taking liraglutide (Victoza) had a 28% lower risk.
DRINKING ALCOHOL WEEKLY COULD BE CONNECTED TO 61 DIFFERENT DISEASES, STUDY FINDS The GLP-1 drugs were .
